Peptide Initiative

Peptide profile · Cosmetic

Palmitoyl Tetrapeptide-7

Anti-inflammatory matrikine peptide that reduces IL-6-driven inflammaging for calmer, more youthful skin.

Limited human trialsResearch compound
Susceptible to enzymatic degradation; palmitoyl anchor reduces proteolytic cleavage rate compared to unmodified peptideHalf-life
Enhanced topical penetration via palmitoyl lipid modification enabling membrane interaction and dermal deliveryBioavailability
694.9Molecular weight, Da

Molecular formula

C34H62N8O7

CAS number
221227-05-0
PubChem
10078408
Developed · 2005
Sederma research team, Sederma S.A. (part of Croda International)

Amino acid sequence

Pal-Gly-Gln-Pro-Arg (palmitoylated GQPR tetrapeptide)

Anti-InflammatoryDirectly reduces IL-6 secretion in keratinocytes and fibroblasts, addressing the chronic inflammation that accelerates skin aging.

8.8

Anti-AgingModulates inflammaging pathways and senescence-associated secretory phenotype to slow age-related skin deterioration at the cellular level.

8.2

Skin Barrier SupportStimulates laminin and nidogen production at the dermal-epidermal junction, strengthening structural integrity and barrier resilience.

8.0

Ratings out of 10.

3 % – 10 ppm

Every documented dose level

PhaseDoseFrequency
OngoingUnder 10 ppm (<0.001%) in finished productOnce or twice daily
~2 months~3% trade solution (Matrixyl 3000 blend)Twice daily
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for individuals with aging skin showing signs of chronic low-grade inflammation & those seeking to reduce uv-damage-related skin aging (photoaging)

Best for

  • Individuals with aging skin showing signs of chronic low-grade inflammation

    Palmitoyl Tetrapeptide-7 is particularly well-suited for individuals focused on individuals with aging skin showing signs of chronic low-grade inflammation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Those seeking to reduce UV-damage-related skin aging (photoaging)

    Palmitoyl Tetrapeptide-7 is particularly well-suited for individuals focused on those seeking to reduce uv-damage-related skin aging (photoaging). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • People looking for synergistic peptide therapy in Matrixyl 3000 products

    Palmitoyl Tetrapeptide-7 is particularly well-suited for individuals focused on people looking for synergistic peptide therapy in matrixyl 3000 products. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Individuals with sensitive or reactive skin benefiting from anti-inflammatory peptides

    Palmitoyl Tetrapeptide-7 is particularly well-suited for individuals focused on individuals with sensitive or reactive skin benefiting from anti-inflammatory peptides. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for cosmetic supportConsult your healthcare provider for alternatives to Palmitoyl Tetrapeptide-7 based on your specific needs and medical history
Alternative cosmetic peptidesGHK-Cu (Copper Peptide)Argireline (Acetyl Hexapeptide-3)Matrixyl (Palmitoyl Pentapeptide-4)
Non-peptide cosmetic approachesRetinol/RetinoidsHyaluronic acid serumsVitamin C serums

Do not use if

  • Known hypersensitivity to palmitoyl tetrapeptide-7 or formulation excipients
  • Active skin infections at the application site
  • Severely compromised skin barrier with active inflammation requiring medical intervention
  • No known systemic contraindications at cosmetic concentrations

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Palmitoyl Tetrapeptide-7 use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Palmitoyl Tetrapeptide-7 with similar peptides to find the best fit for your goals.

Route

Palmitoyl Tetrapeptide-7 is administered Topical—no injection required

Best sites

  • Not applicable—this is not an injectable formulation

The Palmitoyl Tetrapeptide-7 dosing protocol covers how it is taken.

4 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

Palmitoyl tetrapeptide-7 (Eyeliss) shows excellent safety for periocular use with minimal irritation potential (Draize score <0.5 at 2% concentration).

No serious adverse events in cosmetic formulations used for 15+ years. Eye irritation testing per OECD 404 confirms safety; no systemic toxicity in repeat-dose oral studies. Mild local effects limited to topical application site with no dermal penetration.

Clinical efficacy measured through non-invasive imaging (ultrasound, photography analysis) demonstrates edema reduction in periocular area with 25-40% visible improvement in eye puffiness after 4 weeks application.

Lymphatic circulation enhancement quantified through fluorescence microlymphography studies. Safety dermatology panel testing confirms ISO 10993 biocompatibility with no irritation at concentrations up to 3%.


Common side effects · experienced by some users

Mild Redness

Temporary mild redness at application site in sensitive individuals. Generally self-resolving within 15-30 minutes.

Management
Perform patch test before first use. If persistent, reduce application frequency.

Slight Tingling

Brief tingling sensation upon application, particularly on skin with compromised barrier.

Management
Normal response for active peptides. Should subside quickly. Ensure skin barrier is intact.

Mild Irritation with Other Actives

Potential for additive mild irritation when layered with multiple active ingredients simultaneously.

Management
Simplify skincare routine. Apply peptide products separately from retinoids or strong acids.

Dryness

Occasional dryness when combined with drying formulations or in very arid environments.

Management
Follow peptide serum with a hydrating moisturizer to seal in benefits.

Serious side effects

Paradoxical Inflammatory Response

In rare cases of high sensitivity or very high concentrations, the peptide could potentially trigger an inflammatory response rather than suppressing it, causing skin redness, irritation, or dermatitis.

Management
Start with low concentrations and patch test; gradually increase concentration over 1-2 weeks; discontinue if irritation or inflammation develops; avoid combining with other anti-inflammatory peptides at high concentrations.

Less commonAllergic Contact Dermatitis

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Palmitoyl Tetrapeptide-7
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Palmitoyl Tetrapeptide-7 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafePalmitoyl Tripeptide-1 — May be used together under medical guidance.
  • SafeHyaluronic Acid — May be used together under medical guidance.
  • SafeNiacinamide — May be used together under medical guidance.

With medications

  • CautionStrong Chemical Peels — Use with caution—discuss with your healthcare provider.
  • CautionHigh-Concentration Retinoids (initially) — Use with caution—discuss with your healthcare provider.
  • CautionStrong Oxidizing Agents — Use with caution—discuss with your healthcare provider.

With supplements

  • SafeMultivitamins — Generally safe to take alongside Palmitoyl Tetrapeptide-7. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Limited human trials · first signs weeks 1-4

Evidence level

Limited human trials

60/100

Regulatory status

Research compound

Onset of effects

Moderate

(1-2 weeks)


How it works

Palmitoyl-tetrapeptide-7 (Matrixyl 3000) is a lipidated signal peptide that both stimulates collagen production AND reduces inflammation in skin.

By combining collagen-building with anti-inflammatory effects, it addresses multiple aging mechanisms at once, improving skin texture, firmness, and reducing redness or irritation.

The deeper mechanism

Palmitoyl-tetrapeptide-7 (Matrixyl 3000) is a four-amino acid peptide conjugated to palmitic acid that combines signal peptide-mediated fibroblast activation with anti-inflammatory effects.

The lipid moiety enhances skin penetration and bioavailability, while the tetrapeptide sequence activates TGF-β-responsive fibroblasts to increase type I and III collagen synthesis and dermal matrix deposition.

Additionally, palmitoyl-tetrapeptide-7 inhibits pro-inflammatory cytokine production (TNF-α, IL-6) and suppresses NF-κB activation in dermal cells, reducing chronic inflammation associated with photoaging.

The dual collagen-stimulating and anti-inflammatory mechanism addresses both structural aging (collagen loss) and inflammatory aging (oxidative stress and cytokine-driven matrix degradation), producing more comprehensive anti-aging benefits than single-mechanism peptides.


What to expect

  1. Weeks 1-4

    What you might notice

    • Anti-inflammatory signaling begins reducing IL-6 levels in skin
    • Early improvements in skin calmness and reduced reactivity
    • Skin texture may feel smoother and more even

    What's normal

    • Full integration of Palmitoyl Tetrapeptide-7 into physiological systems is established
    • Long-term Palmitoyl Tetrapeptide-7 response remains personalized to your physiology
    • Palmitoyl Tetrapeptide-7 tolerance is well-maintained with consistent dosing

    What's next

    • Maintain your established Palmitoyl Tetrapeptide-7 protocol for sustained benefits
    • Continue periodic monitoring to confirm Palmitoyl Tetrapeptide-7 efficacy
    • Review comprehensive Palmitoyl Tetrapeptide-7 response with your provider
  2. Weeks 4-12

    What you might notice

    • Sustained reduction in inflammaging markers
    • Improvements in skin tone and reduced redness from chronic inflammation
    • Laminin and nidogen production enhance dermal-epidermal junction integrity

    What's normal

    • Palmitoyl Tetrapeptide-7 is now achieving steady-state pharmacokinetics
    • Measurable changes aligned with Palmitoyl Tetrapeptide-7's mechanism may appear
    • Initial adjustment effects typically resolve by this point

    What's next

    • Maintain Palmitoyl Tetrapeptide-7 dosing exactly as established
    • Track progress toward intended outcomes in detail
    • Review lab work or biomarker changes with your healthcare team
  3. Weeks 12-24+

    What you might notice

    • Cumulative anti-inflammatory benefits produce visible improvements in skin firmness and resilience
    • When combined with Palmitoyl Tripeptide-1, comprehensive anti-aging results including wrinkle reduction and improved elasticity

    What's normal

    • Full therapeutic effects of Palmitoyl Tetrapeptide-7 are well-characterized at this point
    • Maintenance of Palmitoyl Tetrapeptide-7's therapeutic effects is typical
    • Tolerance patterns with Palmitoyl Tetrapeptide-7 are generally stable over months

    What's next

    • Comprehensive assessment of Palmitoyl Tetrapeptide-7 efficacy should be conducted
    • Discuss long-term continuation, cycling, or protocol modifications
    • Continue regular monitoring of relevant biomarkers or symptoms

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Palmitoyl Tetrapeptide-7 over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

What is inflammaging and how does Palmitoyl Tetrapeptide-7 address it?

Inflammaging is chronic low-grade inflammation that increases with age, driven partly by senescent cells releasing pro-inflammatory cytokines like IL-6. This persistent inflammation degrades collagen, breaks down the extracellular matrix, and accelerates skin aging. Palmitoyl Tetrapeptide-7 directly reduces IL-6 secretion, helping to quiet this inflammatory cycle and protect the skin matrix from inflammation-driven degradation.

Can Palmitoyl Tetrapeptide-7 be used alone or only in Matrixyl 3000?

While most effective as part of Matrixyl 3000 with Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7 can be used independently for its anti-inflammatory benefits. It is particularly useful in formulations targeting sensitive, reactive, or inflammation-prone skin. However, for comprehensive anti-aging results including collagen building, the synergistic combination in Matrixyl 3000 is recommended.

How does this differ from other anti-inflammatory skincare ingredients?

Unlike broad anti-inflammatory botanicals (like centella or green tea), Palmitoyl Tetrapeptide-7 specifically targets IL-6 cytokine signaling in skin cells, providing a more targeted approach to inflammaging. It also stimulates structural proteins (laminin, nidogen) at the dermal-epidermal junction, offering both anti-inflammatory and structural repair benefits that botanical anti-inflammatories do not provide.

Is Palmitoyl Tetrapeptide-7 the same as Palmitoyl Tetrapeptide-3?

Yes. Palmitoyl Tetrapeptide-7 was formerly known as Palmitoyl Tetrapeptide-3 (and marketed as Rigin). The name was updated to Palmitoyl Tetrapeptide-7 under INCI nomenclature revisions, but the molecule and its properties are identical.

Does Palmitoyl Tetrapeptide-7 help with sun damage?

Yes. Research shows it reduces IL-6 secretion specifically in UVB-stressed keratinocytes, meaning it helps mitigate the inflammatory response triggered by UV exposure. While not a sunscreen replacement, it can help reduce the inflammation-driven damage that accelerates photoaging when used as part of a post-sun or daily anti-aging regimen.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Palmitoyl Tetrapeptide-7, on one page.

Palmitoyl Tetrapeptide-7 dosing protocol

Medical disclaimer

Palmitoyl Tetrapeptide-7 is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 11, 2026

3 % – 10 ppm Once or twice daily or twice daily · onset 1-2 weeks
Open the Palmitoyl Tetrapeptide-7 calculatorPalmitoyl Tetrapeptide-7 calculator